Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 10/20 | 1.00 |
| ▸ | CSF1R | P07333 | 5/20 | 0.71 |
| ▸ | KIT | P10721 | 3/20 | 0.67 |
| ▸ | HSF1 | Q00613 | 1/20 | 0.65 |
| ▸ | KDR | P35968 | 2/20 | 0.61 |
| ▸ | RAF1 | P04049 | 1/20 | 0.61 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.61 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.61 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.59 |
| ▸ | TEK | Q02763 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | LCK | P06239 | 1/20 | 0.58 |
| ▸ | SRC | P12931 | 1/20 | 0.58 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7840189 | 0.96 | BRAF (0.93) | BRAFCSF1RKITHSF1KDR | |
| SCHEMBL7840187 | 0.95 | BRAF (0.91) | BRAFCSF1RKITHSF1KDR | |
| SCHEMBL22364997 | 0.94 | BRAF (0.88) | BRAFCSF1RKITHSF1KDR | |
| SCHEMBL5897226 | 0.93 | BRAF (0.87) | BRAFCSF1RKITHSF1TRPV1 | |
| SCHEMBL6979265 | 0.87 | BRAF (0.77) | BRAFCSF1RHSF1RAF1KDM4E | |
| SCHEMBL5897251 | 0.87 | BRAF (0.76) | BRAFCSF1RHSF1RAF1KDM4E | |
| SCHEMBL5000987 | 0.85 | BRAF (0.78) | BRAFCSF1RKITKDRRAF1 | |
| SCHEMBL5897487 | 0.84 | CSF1R (0.81) | BRAFCSF1RHSF1RAF1KDM4E | |
| SCHEMBL6975716 | 0.84 | BRAF (0.72) | BRAFCSF1RHSF1RAF1KDM4E | |
| SCHEMBL5897048 | 0.83 | BRAF (0.71) | BRAFCSF1RHSF1PDGFRBPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4108248-A1 | C. NOVYI FOR THE TREATMENT OF SOLID TUMORS IN HUMANS | Biomed Valley Discoveries, Inc. (US) | 2022-12-28 | — | — | EP | disclosed |
| US-20220378852-A1 | C. NOVYI FOR THE TREATMENT OF SOLID TUMORS IN HUMANS | THE JOHNS HOPKINS UNIVERSITY | 2022-12-01 | — | — | US | disclosed |
| EP-3730146-B1 | C. NOVYI FOR THE TREATMENT OF SOLID TUMORS IN HUMANS | BIOMED VALLEY DISCOVERIES INC (US) | 2022-05-04 | — | — | EP | disclosed |
| US-11246859-B2 | Methods and compositions for treating non-ERK MAPK pathway inhibitor-resistant cancers | BIOMED VALLEY DISCOVERIES, INC. (US) | 2022-02-15 | — | — | US | disclosed |
| EP-3082800-B1 | CANCER TREATMENT USING COMBINATIONS OF ERK AND RAF INHIBITORS | BIOMED VALLEY DISCOVERIES INC (US) | 2022-02-02 | — | — | EP | disclosed |
| US-11007183-B2 | Cancer treatments using combinations of PI3K/Akt pathway and ERK inhibitors | BIOMED VALLEY DISCOVERIES, INC. (US) | 2021-05-18 | — | — | US | disclosed |
| US-20210085663-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER WITH ATYPICAL BRAF MUTATIONS | BIOMED VALLEY DISCOVERIES, INC. | 2021-03-25 | — | — | US | disclosed |
| US-20210038587-A1 | METHODS AND COMPOSITIONS FOR TREATING NON-ERK MAPK PATHWAY INHIBITOR-RESISTANT CANCERS | BIOMED VALLEY DISCOVERIES, INC. | 2021-02-11 | — | — | US | disclosed |
| US-10881646-B2 | Methods and compositions for treating non-ERK MAPK pathway inhibitor-resistant cancers | BIOMED VALLEY DISCOVERIES, INC. (US) | 2021-01-05 | — | — | US | disclosed |
| US-20200339531-A1 | CRYSTALLINE FORMS OF C21H22Cl2N4O2 | VERTEX PHARMACEUTICALS INCORPORATED | 2020-10-29 | — | — | US | disclosed |
| WO-2015095819-A2 | CANCER TREATMENT USING COMBINATIONS OF ERK AND RAF INHIBITORS | BIOMED VALLEY DISCOVERIES, INC. (US) | 2015-06-25 | — | — | WO | disclosed |
| WO-2015095842-A2 | METHODS AND COMPOSITIONS FOR TREATING NON-ERK MAPK PATHWAY INHIBITOR-RESISTANT CANCERS | BIOMED VALLEY DISCOVERIES, INC. (US) | 2015-06-25 | — | — | WO | disclosed |
| WO-2014160967-A9 | C. NOVYI FOR THE TREATMENT OF SOLID TUMORS IN NON-HUMAN ANIMALS | BIOMED VALLEY DISCOVERIES, INC. (US) | 2014-12-24 | — | — | WO | disclosed |
| WO-2014160950-A1 | C. NOVYI FOR THE TREATMENT OF SOLID TUMORS IN HUMANS | BIOMED VALLEY DISCOVERIES, INC. (US) | 2014-10-02 | — | — | WO | disclosed |
| WO-2014160967-A2 | C. NOVYI FOR THE TREATMENT OF SOLID TUMORS IN NON-HUMAN ANIMALS | BIOMED VALLEY DISCOVERIES, INC. (US) | 2014-10-02 | — | — | WO | disclosed |
| US-7060700-B2 | Amide derivatives useful as inhibitors of the production of cytokines | ASTRAZENECA AB (SE) | 2006-06-13 | — | — | US | disclosed |
| US-20030105142-A1 | Amide derivatives useful as inhibitors of the production of cytokines | ASTRAZENECA AB | 2003-06-05 | — | — | US | disclosed |
| US-6432949-B1 | Amide derivatives useful as inhibitors of the production of cytokines | ASTRAZENECA AB (SE) | 2002-08-13 | — | — | US | disclosed |
| EP-1102750-A1 | AMIDE DERIVATIVES USEFUL AS INHIBITORS OF THE PRODUCTION OF CYTOKINES | AstraZeneca AB (SE) | 2001-05-30 | — | — | EP | disclosed |
| WO-2000007991-A1 | AMIDE DERIVATIVES USEFUL AS INHIBITORS OF THE PRODUCTION OF CYTOKINES | ASTRAZENECA AB (SE) | 2000-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11007183-B2 | Cancer treatments using combinations of PI3K/Akt pathway and ERK inhibitors | KRAS, BRAF, NRAS | BRAF 2/4885CSF1R 1920/4885KIT 1021/4885 |
| US-10881646-B2 | Methods and compositions for treating non-ERK MAPK pathway inhibitor-resistant cancers | MAP3K1, MAP3K2, MAP3K6 | BRAF 40/4885CSF1R 3809/4885KIT 601/4885 |
| US-20220378852-A1 | C. NOVYI FOR THE TREATMENT OF SOLID TUMORS IN HUMANS | HCCS, MKI67, PBK | BRAF 224/4885CSF1R 2558/4885KIT 190/4885 |
| US-20210085663-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER WITH ATYPICAL BRAF MUTATIONS | BRAF, NRAS, KRAS | BRAF 1/4885CSF1R 2384/4885KIT 558/4885 |
| US-20210038587-A1 | METHODS AND COMPOSITIONS FOR TREATING NON-ERK MAPK PATHWAY INHIBITOR-RESISTANT CANCERS | MAP3K1, MAP3K2, MAP3K6 | BRAF 40/4885CSF1R 3809/4885KIT 601/4885 |
| US-20030105142-A1 | Amide derivatives useful as inhibitors of the production of cytokines | IL6, IL6ST, IL2 | BRAF 1764/4885CSF1R 273/4885KIT 635/4885 |
| US-11246859-B2 | Methods and compositions for treating non-ERK MAPK pathway inhibitor-resistant cancers | MAP3K1, MAP3K2, MAP3K6 | BRAF 40/4885CSF1R 3809/4885KIT 601/4885 |
| US-20200339531-A1 | CRYSTALLINE FORMS OF C21H22Cl2N4O2 | CYP2F1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CA4 | BRAF 1621/4885CSF1R 2921/4885KIT 1741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.